Cardiff, UK – Diurnal Limited, a specialty pharmaceutical company committed to the development and commercialization of orphan drugs targeting chronic endocrine diseases, today announced the appointment of Mr Ian Ardill as Chief Financial Officer. Mr Ardill will also join the Board of Directors; both positions effective immediately.
Ian brings 20 years of financial and accounting experience to his role at Diurnal, most recently as CFO at Lombard Medical, where he led the company financially through the late stages of FDA pre-market approval and the commencement of US commercial operations. On the financing front, he managed a £22m AIM fundraising and the company’s $55m NASDAQ IPO, involving an AIM delisting and re-domicile.
Prior to Lombard Medical, Mr.Ardill was Chief Financial Officer at Biocompatibles International and played a leading role in transforming the company from a loss-making to a profitable enterprise. He also managed the successful £177m sale of the business to BTG Plc in 2011. Other management experience includes Novartis Pharmaceuticals, the Compass Group and NHA International. Ian qualified as a chartered accountant with Grant Thornton.
Martin Whitaker, CEO of Diurnal, stated:
“We are extremely pleased to welcome Ian to the Diurnal executive team. His impressive industry track record demonstrates an ability to create value and growth for companies where he has been part of a management team. Diurnal look forward to utilising his extensive experience as we continue to advance the development of our unique and highly specialized pipeline of drugs towards market authorisation”
Please direct all enquiries to:
Martin Whitaker, CEO
+44 (0)871 716 8848